Physician profile
Jeffrey K Lander
NPI 1174566046
$1,722.40
in general payments reported to CMS, 2019-2025
24 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $168 · 2021: $219 · 2022: $308 · 2023: $233 · 2024: $334 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $398.84 | 2019-2025 | |
| Mimedx Group, INC. | $213.07 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $151.13 | 2022 | |
| Incyte Corporation | $137.35 | 2023 | Opzelura |
| Merz North America, INC. | $86.98 | 2019-2024 | Xeomin |
| Janssen Scientific Affairs, LLC | $86.30 | 2020 | |
| Dusa Pharmaceuticals, INC. | $66.34 | 2019 | |
| Janssen Biotech, INC. | $64.35 | 2019-2024 | Tremfya |
| Lilly USA, LLC | $63.58 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $61.81 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $49.31 | 2019 | |
| Leo Pharma INC. | $39.62 | 2019-2024 | Adbry |
| Pfizer INC. | $37.76 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $37.32 | 2020-2021 | |
| Amgen INC. | $36.37 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $32.69 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $28.42 | 2025 | |
| Surgenex LLC | $24.04 | 2025 | Surmatrix, Pellograft, Surgraft |
| Celgene Corporation | $20.91 | 2019 | |
| Abbvie INC. | $20.47 | 2021 | |
| Epi Health, LLC | $19.43 | 2019 | |
| Misonix INC | $17.71 | 2021 | |
| Nabriva Therapeutics, Plc | $17.60 | 2020 | |
| Almirall LLC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.